01—Abstract
Summary
Summary of the 10-K filed February 24, 2026. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. reported total sales of $65.0 billiona for the fiscal year 2025, a modest 1% increase year-over-year (2% excluding foreign exchange impact).
This growth was primarily driven by strong performance in the oncology franchise, particularly Keytruda, and the Animal Health segment, alongside contributions from the cardiometabolic and respiratory portfolio, including the launch of Winrevair, and the acquisition of Verona Pharma which added Ohtuvayre. However, the company faced headwinds in its vaccines segment, notably a significant decline in Gardasil/Gardasil 9 sales in China due to inventory issues and local competition, as well as lower sales in the immunology and virology segments. Merck continued to bolster its pipeline through strategic business development, including the acquisition of Cidara Therapeutics and Verona Pharma, and exclusive license agreements for promising early-stage candidates.
The company also advanced its late-stage pipeline with numerous regulatory submissions and positive Phase 3 trial results across various therapeutic areas. Despite revenue growth, the company announced a significant restructuring program aimed at optimizing operations and supporting future growth, expected to result in annual cost savings. Investors should monitor upcoming patent expirations for key products like Januvia and Janumet, and the ongoing impact of regulatory changes and pricing pressures, particularly from the Inflation Reduction Act, which is expected to affect Keytruda's U.S. sales in the future.
02—Key points
Key Highlights
- Total sales reached $65.0 billion in 2025, a 1% increase (2% excluding FX) driven by oncology, animal health, and cardiometabolic/respiratory segments.
- Keytruda and Keytruda Qlex sales grew 7% to $31.7 billion, demonstrating continued strength in the oncology franchise.
- Gardasil/Gardasil 9 sales declined significantly (-39%) due to lower demand in China and inventory management issues.
- Acquisitions of Verona Pharma and Cidara Therapeutics, along with strategic licensing agreements, bolstered Merck's pipeline and product portfolio.
- A new restructuring program was announced, aiming for significant cost savings and operational efficiencies.
- The company faces significant patent expirations for Januvia and Janumet in 2026, with expected material sales declines.
- The Inflation Reduction Act's drug price negotiation program is expected to impact Keytruda sales starting in 2029.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 24, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $65.01B$64.17B | +1.3% |
| Cost of Revenue | $16.38B$15.19B | +7.8% |
| Gross Profit | $48.63B$48.98B | −0.7% |
| R&D Expenses | $15.79B$17.94B | −12.0% |
| SG&A Expenses | $10.73B$10.82B | −0.8% |
| Net Income | $18.25B$17.12B | +6.6% |
| EPS (Basic) | $7.30$6.76 | +8.0% |
| EPS (Diluted) | $7.28$6.74 | +8.0% |
| Shares Outstanding (Basic) | 2.50B2.53B | −1.2% |
| Shares Outstanding (Diluted) | 2.51B2.54B | −1.3% |
05—Questions
Frequently Asked Questions
What were Merck's key growth drivers in 2025?
Merck's key growth drivers in 2025 were its oncology franchise, particularly Keytruda, and the Animal Health segment. The cardiometabolic and respiratory portfolio also contributed, bolstered by the launch of Winrevair and the acquisition of Verona Pharma. Strategic business development activities, including the acquisition of Cidara Therapeutics, also aimed to drive future growth.
What challenges did Merck face in 2025?
Merck faced challenges including a significant decline in Gardasil/Gardasil 9 sales in China due to inventory issues and local competition. Sales in the immunology and virology segments also decreased. Furthermore, patent expirations for key products like Januvia and Janumet in 2026 are expected to impact future sales, and the company announced a restructuring program which indicates a need for operational optimization.
How will the Inflation Reduction Act (IRA) impact Merck?
The IRA is expected to have a material impact on Merck's U.S. sales of Keytruda starting in 2029, as it has been selected for government price setting. Additionally, Januvia and Janumet are already subject to government-set prices effective in early 2026 and 2027, respectively, which are expected to significantly reduce their U.S. sales following loss of market exclusivity.
What is Merck's strategy for its pipeline and future growth?
Merck's strategy focuses on advancing its science-led approach through new product approvals and launches, strong clinical execution, and strategic business development to augment its internal pipeline with external innovation. The company is diversifying its oncology portfolio across immuno-oncology, precision molecular targeting, and tissue targeting, and is advancing its pipeline in areas such as cardiometabolic, respiratory, and immunology.
06—Continue